Clinical Endocannabinoid Deficiency: Myth, Theory or Reality?
Clinical endocannabinoid deficiency is a hypothesis that emerged some years ago to explain certain functional disorders that are difficult to treat, such as migraine, fibromyalgia or irritable bowel syndrome (IBS).
The idea is simple and seemed promising, but it is a hypothesis that has not been investigated in much greater depth in recent years. That is why we explain here what it is, what is known, and why there are still so many open questions about clinical endocannabinoid deficiency: how it relates to your health and whether products such as CBD oil could help to counter it.
What is clinical endocannabinoid deficiency (CECD)?
Clinical endocannabinoid deficiency, known by the acronym CECD (Clinical Endocannabinoid Deficiency), is a scientific hypothesis proposing that, in some people, the body produces fewer endocannabinoids than needed or that the endocannabinoid system does not work with adequate efficiency. As a result, certain symptoms linked to some conditions may appear or worsen (1).
This is where public interest comes in, as many people wonder whether substances such as CBD (cannabidiol), one of the best-known cannabinoids in hemp, could influence that system. Part of CBD’s popularity is due to the fact that it is not psychoactive (it does not get you “high”) and that it is marketed in Europe as a wellness product in various formats.
The clinical endocannabinoid deficiency hypothesis
The clinical endocannabinoid deficiency hypothesis was proposed by the researcher Ethan Russo in 2004, who suggested that some chronic disorders might share an underlying dysfunction of the endocannabinoid system, although the concept remains a theory under investigation (1).
CECD is usually described as a state in which the body would have insufficient levels of endocannabinoids (such as anandamide or 2-AG) or an altered functioning of its network of receptors, enzymes and signals (2). It is proposed above all for disorders with chronic symptoms and unclear mechanisms, such as:
- Migraine
- Fibromyalgia
- Irritable bowel syndrome (IBS)
Among the symptoms commonly mentioned are persistent pain, frequent migraines, digestive discomfort, sleep disturbances, fatigue and chronic stress. Even so, these symptoms do not confirm CECD, as they can appear in many other conditions.
The problem is that, although this hypothesis is attractive and seems to answer some questions about certain conditions, there is still no clinical consensus confirming CECD as an established diagnostic syndrome; at present it has no official clinical diagnosis and no standardised tests (3).
In that context, CBD is often presented as a simple way to support the endocannabinoid system, but that conclusion is not as straightforward as is sometimes communicated online.
Endocannabinoid deficiency begins in the endocannabinoid system
To understand CECD, you first need to understand the endocannabinoid system (ECS). It is a biological network that, broadly speaking, is made up of:
- Endocannabinoids (messengers produced by the body itself, such as AEA and 2-AG)
- Receptors (especially CB1 and CB2)
- Enzymes that produce and break them down (for example FAAH for anandamide)
The endocannabinoid system is still, in part, a definition in evolution. In fact, the term “endocannabinoid” is partly a historical label (it was coined after studying cannabis) rather than a closed definition. We now know that its messengers (ligands) and enzymes interact with many other pathways in the body (4), so defining exactly what a “deficiency” would be is difficult.
This matters because CBD can interact with multiple proteins and biological pathways, some related to the endocannabinoid system and others not.
What research supports the endocannabinoid deficiency theory?
One of the most frequently cited arguments in favour of CECD comes from studies that have observed lower levels of endocannabinoids in the fluid that surrounds the brain and spinal cord (cerebrospinal fluid, CSF) of patients with chronic migraine (5).
It is worth noting that, although anandamide (AEA) and 2-AG can be measured in research settings, there are no routine clinical tests to diagnose CECD, and their levels vary depending on the tissue and the moment.
But in some conditions there is no “deficiency” — rather the opposite. For example, in fibromyalgia some studies have found elevated endocannabinoids (6, 7). That complicates the idea of a deficiency that can be generalised.
Likewise, low levels may be a marker, not the cause. Endocannabinoids are released in response to neurotransmitters (the chemical messengers of the nervous system) such as glutamate, GABA, serotonin or acetylcholine. If the activity of those systems changes, so will endocannabinoid levels, without this meaning a primary deficiency.
This also helps to understand why it is not enough to assume that adding cannabinoids (including CBD) automatically corrects a problem; the system and its metabolic pathways may behave differently depending on the person, the tissue or the moment.
How does the endocannabinoid system work?
Imagine the ECS as a fine-tuning system. When the body detects that a process is becoming unbalanced (excessive pain, inflammation, stress), endocannabinoids act as modulating signals: they do not usually “switch on” or “switch off” completely, but instead adjust the intensity.
But this fine-tuning can also be disrupted in other ways, such as:
- Changes in neurotransmitter release
- Changes in receptor sensitivity or density
- An increase or decrease in enzymes such as FAAH or MAGL
That is why the key question is not just “is there too little anandamide?”, but why there is too little, in which tissues, for how long and with what consequences.
How could CBD help to counter endocannabinoid deficiency?
CBD can increase anandamide by inhibiting the enzyme that breaks it down (FAAH), which could translate into a stronger endocannabinoid signal. Even so, although CBD may modulate a specific pathway, that does not mean it will correct the problem in a localised way.
In other words, CBD is a complementary compound with promising studies for conditions such as anxiety or some types of pain. But the direct leap to CBD as a solution for clinical endocannabinoid deficiency is not yet supported by conclusive clinical trials.
Scientific evidence on endocannabinoid deficiency vs marketing
The narrative that the body needs phytocannabinoids (the cannabinoids from the cannabis plant) in order to avoid illness has become widespread, but saying that the endocannabinoid system exists does not mean the body needs cannabis to function well — just as having an opioid system does not imply that we must take opioids to supplement it.
This does not mean that products containing cannabinoids, such as CBD oil or CBD physiotherapy, have no therapeutic potential. There are many studies that support the benefits of CBD, but it is important to keep realistic expectations when talking about clinical endocannabinoid deficiency, since many claims are based on hypotheses or on preliminary evidence.
Conclusion: myth, theory or reality?
CECD is an interesting hypothesis, and there are findings compatible with that idea in some contexts (e.g. migraine), but the endocannabinoid system is complex, with many pathways still undefined. While CBD has medicinal properties, the direct extrapolation to CBD/THC recommendations is premature.
CECD could become a relevant piece in understanding some complex disorders. But the available evidence does not yet justify turning the hypothesis into health marketing.
Disclaimer
This article is for informational purposes only and does not constitute medical advice. The information provided here may complement, but never replace, the diagnosis or treatment of a healthcare professional. If you live with migraine, fibromyalgia, irritable bowel syndrome or another chronic disorder, or you take medication, consult your doctor before adding CBD to your routine. Cannactiva products are not medicines: they are marketed in accordance with European regulations for external, aromatic or ornamental use. Research on CBD continues to evolve and new evidence may have emerged since the date of publication.
References
- Russo E. B. (2004). Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro endocrinology letters, 25(1-2), 31–39.
- Smith, S. C., & Wagner, M. S. (2014). Clinical endocannabinoid deficiency (CECD) revisited: can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro endocrinology letters, 35(3), 198–201.
- Cogan P. S. (2020). Practical Considerations of Hypotheses and Evidence in Cannabis Pharmacotherapy: Refining Expectations of Clinical Endocannabinoid Deficiency. Journal of dietary supplements, 17(5), 608–624. https://doi.org/10.1080/19390211.2020.1769246
- Pertwee, R. G., Howlett, A. C., Abood, M. E., et al. (2010). International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacological reviews, 62(4), 588–631. https://doi.org/10.1124/pr.110.003004
- Russo E. B. (2016). Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes. Cannabis and cannabinoid research, 1(1), 154–165. https://doi.org/10.1089/can.2016.0009
- Stensson, N., Ghafouri, N., Ernberg, M., et al. (2018). The Relationship of Endocannabinoidome Lipid Mediators With Pain and Psychological Stress in Women With Fibromyalgia: A Case-Control Study. The journal of pain, 19(11), 1318–1328. https://doi.org/10.1016/j.jpain.2018.05.008
- Kaufmann, I., Schelling, G., Eisner, C., et al. (2008). Anandamide and neutrophil function in patients with fibromyalgia. Psychoneuroendocrinology, 33(5), 676–685. https://doi.org/10.1016/j.psyneuen.2008.02.009
